DAFTAR PUSTAKA

American Medical Association, 2008. American Medical Association Complete

Guide to Prevention and Wellness. Wiley, United State of America.

American Cancer Society, 2014. 'How is breast cancer staged?'. URL:

http://www.cancer.org /cancer/ breastcancer/ detailedguide/breast-cancer-

staging (diakses tanggal 6/3/2014).

Badan Penelitian dan Pengembangan Kesehatan, 2007. 'Laporan Nasional

Riskesdas 2007. URL: http://www.litbang.depkes.go.id/bl_riskesdas2007
(diakses tanggal 3/3/2014).
Badan Penelitian dan Pengembangan Kesehatan, 2013. 'Laporan Nasional
Riskesdas 2007. URL: http://www.litbang.depkes.go.id/bl_riskesdas2007
(diakses tanggal 3/3/2014).
Bodicoat, D.H., Schoemaker, M.J., Jones, M.E., McFadden, E., Griffin, J.,
Ashworth, A., dkk., 2014. Timing of pubertal stages and breast cancer risk:
the Breakthrough Generations Study. Breast cancer research: BCR, 16:
R18.
Carrison, R., 2014. 'National Comprehensive Cancer Network : Adjuvant Therapy
Chemotherapy, Hormonal Therapy' Medscape Pharmacists. URL:
https://www.google.com/#q=hormonal+therapy+algorithm+for+breast+ca
ncer (diakses tanggal 3/4/2014).
Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., dkk.,
2004. A Randomized Trial of Exemestane after Two to Three Years of
Tamoxifen Therapy in Postmenopausal Women with Primary Breast
Cancer. New England Journal of Medicine, 350: 1081–1092.
Cummings, F.J., 2002. Evolving uses of hormonal agents for breast cancer therapy.
Clinical Therapeutics, 24, Supplement 3: C3–C25.
Dranitsaris, G., Verma, S., dan Trudeau, M., 2003. Cost utility analysis of first-line
hormonal therapy in advanced breast cancer: comparison of two aromatase

83
 inhibitors to tamoxifen. American journal of clinical oncology, 26: 289–
296.
Fauci, A.S., 2008. Harrison’s Principles of Internal Medicine Editors, Anthony S.
Fauci ... [et Al.]., 17th ed. McGraw-Hill Medical, New York.
Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., dan Parkin, D.M., 2010.
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
International journal of cancer, 127: 2893–2917.
Gordon, B.L., Shaw, H.S., Kroll, D.J., dan Daniel, B.R., 2010. Breast Cancer
Recurrence and Advanced Disease: Comprehensive Expert Guidance. Duke
University Press, United State of America.
Hans, P., 2010. Medical Management of Advance Disease, dalam: Reed, M.W.,
Audisio, R.A. (Eds.), Springer, New York, hal. 300–303.
Hastuti, S. dan Dwiprahasto, I., M.M.S., 2012. 'Analisis Hubungan Jenis
Kemoterapi dengan Perbaikan Outcome dan Biaya Pengobatan pada Pasien
Kanker Payudara DI RSUD DR. Moewardi'. Universitas Gadjah Mada,
Yogyakarta.
Helms, R.A. dan Quan, D.J., 2006. Textbook of Therapeutics: Drug and Disease
Management, 8th ed. Lippincott Williams & Wilkins, Philadelphia, hal.
2773-2778.
Josefsson, M.L. dan Leinster, S.J., 2010. Aromatase inhibitors versus tamoxifen as
adjuvant hormonal therapy for oestrogen sensitive early breast cancer in
post-menopausal women: Meta-analyses of monotherapy, sequenced
therapy and extended therapy. The Breast, 19: 76–83.
Kementerian Kesehatan, 2013. 'buletin ed mei okk - Penelusuran Google'. URL:
https://www.google.com/#q=buletin+ed+mei+okk (diakses tanggal
4/3/2014).
Kementerian Kesehatan, 2014. Kementrian Kesehatan Republik Indonesia'. URL:
www.depkes.go.id/index.php?vw=2&id_1309000001 (diakses tanggal
7/5/2014).
Kenne, E., Öhlén, J., Jonsson, T., dan Gaston-Johansson, F., 2007. Coping with
Recurrent Breast Cancer: Predictors of Distressing Symptoms and Health-

84
 Related Quality of Life. Journal of Pain and Symptom Management, 34:
24–39.
Massimini, G., Paridaens, R., Lobelle, J., dan Piscitelli, G., 2003. 'Breast cancer
hormonal therapy'. 20030144259.
National Cancer Institute, 2013. 'Breast Cancer Treatment (PDQ®) - National
Cancer Institute' Treatment Option Overview. URL: http://www.cancer.gov
/cancertopics/pdq/treatment/breast/Patient/page5 (diakses tanggal
9/3/2014).
Noe, L.L., Becker 3rd, R.V., Gradishar, W.J., Gore, M., dan Trotter, J.P., 1999. The
cost effectiveness of tamoxifen in the prevention of breast cancer. The
American journal of managed care, 5: S389–406.
Otto, S., 2013. Keperawatan Onkologi. EGC, Jakarta.
Puhalla, S., Bhattacharya, S., dan Davidson, N.E., 2012. Hormonal therapy in breast
cancer: A model disease for the personalization of cancer care. Molecular
Oncology, 6: 222–236.
Puspandari, D.A,. 2014. Model Estimasi Biaya Obat Pasien Kanker Payudara Dan
Faktor Penentu Di Rumah Sakit Di Indonesia, Disertasi, Dr., Unversitas
gadjah Mada, Yogyakarta.
Rafferty, E., 2009. Multidisciplinary Issues for Newly Diagnosed, dalam: MD,
J.K.E., Phd, B.L.S.M., PhD, A.G.T.M. (Eds.), Breast Cancer: A
Multidisciplinary Approach to Diagnosis and Management. Demos
Medical Publishing, hal. 67–82.
Rao, S., Kubisiak, J., dan Gilden, D., 2004. Cost of Illness Associated with
Metastatic Breast Cancer. Breast Cancer Research and Treatment, 83: 25–
32.
Risebrough, N.A., Verma, S., Trudeau, M., dan Mittmann, N., 2007. Cost-
effectiveness of switching to exemestane versus continued tamoxifen as
adjuvant therapy for postmenopausal women with primary breast cancer.
Cancer, 110: 499–508.
Sanchez, A, 2008. pharmacoeconomics principles methods and applications. The
Mc-Graw Hills Companys, 1.

85
Setiawan, D. dan Dwiprahasto, I., M.M.S., 2011. 'Biaya Pengobatan Pasien Kanker
Payudara Stadium Awal Yang Mendapatkan Kemoterapi Kombinasi 5-
Fluorourasil, Doksorubisin, Siklofosfamid (FAC) Dengan Keoterapi
Kombinasi Berbasis Taxan'. Universitas Gadjah Mada.
Sewell, M dan Marczak, M, 2014. 'Using cost analysis in evaluation' The University
of Tucson Arizona. URL: https://www.google.com.br/search?
q=using+cost+analysis+in+evaluation+sewel+2009&hl=id&authuser=0
(diakses tanggal 10/3/2014).
Stopeck, A., 2014. Breast Cancer Treatment & Management. medscape,.
Swart R, 2013. Adjuvant Therapy for Breast Cancer.
Thompson, D., Taylor, D.C.A., Montoya, E.L., Winer, E.P., Jones, S.E., dan
Weinstein, M.C., 2007. Cost-Effectiveness of Switching to Exemestane
after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women
with Early-Stage Breast Cancer. Value in Health, 10: 367–376.
Tim Dharmais, R.K., 2003. Penatalaksanaan Kanker Payudara Terkini, 1st ed.
Yayasan Obor Indonesia, Jakarta.
Tobin, M., 2003. Breast Cancer, dalam: Taylor, R.B. (Ed.), Family Medicine:
Principles and Practice. Springer, New York, hal. 903–907.
Thurlimann, D., Taylor, D.C.A., Montoyo, E.l., Winer, E.P., Jones, S.E., dan
Weinstein, M.C., 2007. Cost-Effectiveness of Switching to Exemestene
after 2 to Years of Therapy with Tamoxifen in Postmenopausal Women with
Early-Stage Breast Cancer. Value in Health, 10: 367-376.
Tsu, V.D., Jeronimo, J., dan Anderson, B.O., 2013. Why the time is right to tackle
breast and cervical cancer in low-resource settings. Bulletin of the World
Health Organization, 91: 683–690.
Venturini, F dan Jhonson, A, 2002. Introduction to pharmacoeconomic principles
and application in pharmacy practice. California journal of health system,
14.1: 6–15.
Vogenberg, F.R., 2001. Introduction to Applied Pharmacoeconomics. McGraw-
Hill, Medical Pub. Division.

86
Walley, T., Haycox, A., dan Boland, A., 2004. Pharmacoeconomics. Churchill
Livingstone, Edinburgh; New York.
Wang, Y., Atkins, D., Foekens, A.J., dan Klijn, G.M.J., 2005. Effects of
chemotherapy and hormonal therapy for early breast cancer on recurrence
and 15-year survival: an overview of the randomised trials. The Lancet, 365:
1687–1717.
World Health Organization, 2014. 'WHO | Breast cancer: prevention and control'
WHO. URL: http://www.who.int/cancer/detection/breastcancer/en/index1.
html (diakses tanggal 3/3/2014).
Yueniwati, Y., Diana, N., Iskandar, A., 2007. Akurasi metode radiokolloid dan blue
dye dalam mnedeteksi limfonodi sentinel dalam mendeteksi kanker
payudara stadium dini. Jurnal Kedokteran Brawijaya, XXIII No.1: .

87